Details for New Drug Application (NDA): 215846
✉ Email this page to a colleague
The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
Summary for 215846
Tradename: | SODIUM NITROPRUSSIDE |
Applicant: | Slate Run Pharma |
Ingredient: | sodium nitroprusside |
Patents: | 0 |
Pharmacology for NDA: 215846
Physiological Effect | Vasodilation |
Suppliers and Packaging for NDA: 215846
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SODIUM NITROPRUSSIDE | sodium nitroprusside | SOLUTION;INTRAVENOUS | 215846 | ANDA | Hainan Poly Pharm. Co., Ltd. | 14335-132 | 14335-132-01 | 1 VIAL in 1 CARTON (14335-132-01) / 50 mL in 1 VIAL |
SODIUM NITROPRUSSIDE | sodium nitroprusside | SOLUTION;INTRAVENOUS | 215846 | ANDA | Hainan Poly Pharm. Co., Ltd. | 14335-133 | 14335-133-01 | 1 VIAL in 1 CARTON (14335-133-01) / 100 mL in 1 VIAL |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 10MG/50ML (0.2MG/ML) | ||||
Approval Date: | Aug 26, 2022 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 20MG/100ML (0.2MG/ML) | ||||
Approval Date: | Aug 26, 2022 | TE: | AP | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 50MG/100ML (0.5MG/ML) | ||||
Approval Date: | Aug 26, 2022 | TE: | AP | RLD: | No |
Complete Access Available with Subscription